Albany Med prize winners: Coronavirus vaccine was years in the making timesunion.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from timesunion.com Daily Mail and Mail on Sunday newspapers.
Washington, D.C., June 03, 2021 (GLOBE NEWSWIRE) The Sabin Vaccine Institute (Sabin) today announced that it has awarded its annual Albert B. Sabin Gold Medal to Barney S. Graham, MD, PhD, deputy director, Vaccine Research Center and chief of the Viral Pathogenesis Laboratory at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Sabin has also granted the Rising Star Award to Nginache Nampota-Nkomba, MBBS, MSc, a research physician an
NIH launches first-in-human, Phase 1 trial assessing investigational nanoparticle influenza vaccine
A first-in-human, Phase 1 trial assessing the safety and immunogenicity of an investigational nanoparticle influenza vaccine designed to provide long-lasting protection against multiple flu virus strains has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland. Healthy participants 18 to 50 years old will receive either a licensed seasonal influenza vaccine or the experimental vaccine, FluMos-v1. Scientists from NIH s National Institute of Allergy and Infectious Diseases (NIAID) developed FluMos-v1 to stimulate antibodies against multiple influenza virus strains by displaying part of the influenza virus hemagglutinin (HA) protein on self-assembling nanoparticle scaffolds. Alicia T. Widge, M.D., of NIAID s Vaccine Research Center (VRC), is the principal investigator of the NIAID-sponsored single-site trial.
HIN
A first-in-human, Phase 1 trial assessing the safety and immunogenicity of an investigational nanoparticle influenza vaccine designed to provide long-lasting protection against multiple flu virus strains has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland. Healthy participants 18 to 50 years old will receive either a licensed seasonal influenza vaccine or the experimental vaccine, FluMos-v1. Scientists from NIH’s National Institute of Allergy and Infectious Diseases (NIAID) developed FluMos-v1 to stimulate antibodies against multiple influenza virus strains by displaying part of the influenza virus hemagglutinin (HA) protein on self-assembling nanoparticle scaffolds. Alicia T. Widge, M.D., of NIAID’s Vaccine Research Center (VRC), is the principal investigator of the NIAID-sponsored single-site trial.